Work

Non-Crosslinked Hyaluronic Acid Redensity 1® Supports Cell Viability, Proliferation, and Collagen Deposition in Early Burn Management

Year: 2025

Type: article

Abstract: Background/Objectives: Burn injuries pose a significant challenge due to tissue damage and impaired healing. Cell-based therapies offer promise by delivering therapeu-tic cells to the wound site. However, effective cell delivery remains a critical hurdle. This study investigates the potential of non-cross-linked hyaluronic acid (HA) as a simple and versatile carrier for delivering autologous keratinocytes and fibroblasts to treat early burn wounds. Methods: Primary keratinocytes and fibroblasts were isolated from uninjured adult skin. In addition, fibroblasts and adipose stem cells (ASC) from polydactyly and progenitor fibroblasts were used. Non-cross-linked HA Redensity 1® (RD1) solutions of varying concentrations were prepared and applied on various in vitro models. Cell viabil-ity, proliferation, migration and collagen stimulation were assessed using standard as-says. Additionally, cells were suspended in Redensity 1 and applied a the in vitro de-epidemalized dermis (DED) wound model to examine cell delivery and tissue refor-mation. Results: Preliminary data demonstrated the feasibility of using non-cross-linked HA RD1 gel as a cell carrier. RD1 gel enhanced cell viability, retention, migration and col-lagen deposition. Histological analysis revealed improved cell adhesion and migration. Conclusions: This study provides valuable insight into the potential of non-cross-linked HA RD1 as a simple and effective delivery vehicle for cell therapies in early burn care. Successful translation of this approach could significantly improve clinical outcomes for burn patients.

Source: Pharmaceutics

DOI: 10.3390/pharmaceutics18010021